

Hepatitis B Virus

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

Trial Status
Completed

Trial Runs In
12 Countries

Trial Identifier
NCT02263079 2006-000977-31
NV25361

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This randomized, controlled, parallel group, open-label multicenter study will evaluate the efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus lamivudine or entecavir compared with an untreated control group in participants with HBeAg positive CHB in the immune tolerant phase. NOTE: STUDY RECRUITMENT HAS BEEN TERMINATED

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT02263079 2006-000977-31 NV25361
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 3 Years & <= 17 Years

Healthy Volunteers
No
